This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...
